Mark Warner is having a busy few days. He's introducing legislation to ease the utility-cost burden on data centers, he's at the center of a Senate fight over spy-law reauthorization, and his social feed is lighting up over his public criticism of Bill Pulte's appointment as acting Director of National Intelligence. That's a lot of frontpage real estate for one senator. Blind Trust has a narrower interest: Warner filed 30 disclosed trades in the last 90 days, and a handful of them land in sectors that his own legislation touches. The calendar is what it is. The filings are what they are.
The Bill on the Table
Warner introduced legislation this week aimed at how data centers are charged for utility costs. The argument is that the current rate structure puts an unfair burden on the facilities powering AI infrastructure. It's a real policy debate. Virginia has more data center capacity than anywhere else in the country, so Warner has a plausible constituent-service rationale. Fine.
What makes the rationale slightly more interesting: on April 13, Warner's disclosures show a purchase of Microsoft. He also picked up a position tagged to a Constellation Energy corporate note (ticker: CORPCEG) on the same day. Constellation is one of the largest power suppliers to data centers in the country and has been aggressively signing long-term energy contracts with hyperscalers including Microsoft. The bill is about data center utility costs. The portfolio contains a data center hyperscaler and a major data center power supplier. The Venn diagram has significant overlap.
Warner sits on the Senate Committee on Banking, Housing, and Urban Affairs with a subcommittee assignment covering Securities, Insurance, and Investment, and separately on the Senate Select Committee on Intelligence. The data center utility bill doesn't fall cleanly under Banking's remit, so we're not calling this a textbook committee conflict. But Warner is a sitting senator from the state most exposed to this legislation's economic effects, and his portfolio moved toward the sector on April 13. The timing is the thing, not an accusation. Readers get to bring their own opinion.
The Intelligence Sideshow
The FISA reauthorization fight puts Warner in a different but equally high-profile spotlight. As the top Democrat on the Senate Intelligence Committee, he's a principal player in whether a surveillance authority that's been law for decades survives the current Senate arithmetic. That's a legitimately important news story about the architecture of American intelligence law.
Social media has layered on a third story: Warner has been publicly vocal about the appointment of Bill Pulte as acting Director of National Intelligence, calling the position one with access to the country's most sensitive secrets. The bluesky chatter this week is thick with it. None of that has a portfolio angle we can find in the filings, so we'll leave it there.
Thirty Trades in Ninety Days
Warner's full disclosure record on Blind Trust shows 30 trades filed in the last 90 days. That's not a quiet quarter. The April 13 batch alone included 11 separate transactions: three sales (two ETF positions and a growth fund) and eight purchases spanning Wells Fargo, Microsoft, Blackstone, Rocket Companies, and several structured notes and private vehicles.
The sales on April 13 are worth noting alongside the purchases. He cleared out positions in three ETFs: ETFIWF, ETFIWD, and ETFVUG (a Vanguard growth fund). Money came out of broad index exposure and went into individual names. That's a rotation, not a panic. Whether it was smart is a separate question.
The alpha record, scored across 13 trades in the sample, is: 5 positive, 8 negative, mean 30-day alpha of negative 3.8 percent versus the S&P 500. Warner is not running the table here. The portfolio is losing ground to the index on a majority of scored trades. The best single result in the sample is the April 13 Rocket Companies purchase, which clocked 8.5 percent alpha at the 30-day mark. The worst is a March 20 sale of Cheniere Energy that underperformed the market by 20.1 percent over 30 days. Eight of thirteen scored trades are underwater relative to the index.
It's a real-world mixed record that any retail investor would recognize.
The Committee Overlap Trades
Here's where it gets structurally interesting, because Warner's committee assignments are unusually broad. Banking. Finance. Intelligence. Rules. Budget. Between those five full committees and their subcommittees, there are very few sectors of the American economy that don't touch something Warner has formal oversight of.
The committee overlap trades the data flags:
- Fifth Third Bancorp (FITB), purchased March 20, 2026. Flagged under Banks. Thirty-day alpha: positive 7.8 percent. Warner sits on Banking, Housing, and Urban Affairs with a subcommittee on Financial Institutions and Consumer Protection. Fifth Third is a regulated bank holding company. The overlap is structural.
- Wells Fargo (WFC), purchased April 13, 2026. Also flagged under Banks. Thirty-day alpha: negative 8.7 percent. Same committee remit. This one didn't work out.
- Microsoft (MSFT), purchased April 13, 2026. Flagged under Technology. Thirty-day alpha: positive 6.3 percent. The Banking Committee's Digital Assets subcommittee covers fintech and digital financial infrastructure. Microsoft's cloud and AI buildout is central to the data center policy debate Warner is now legislating.
- Apple (AAPL), purchased March 20, 2026. Also flagged under Technology. Thirty-day alpha: positive 2.8 percent.
- Amgen (AMGN), sold April 6 and again April 7, 2026. Flagged under Biotechnology. The Finance Committee's Health Care subcommittee covers pharmaceutical and biotech policy. Amgen is one of the largest biotech companies in the world. Warner sold it twice in two days. The 30-day alpha on both sales came in deeply negative: minus 12.9 percent and minus 14.4 percent, meaning Amgen's stock moved against his exit. He sold, and then the stock recovered relative to the market. That's the worst-performing pair in the entire committee-overlap set.
Five committee-overlap trades. Two banks. Two tech names. One biotech sale that went the wrong direction. Three of the five are in sectors where Warner has formal oversight jurisdiction. The system permits this. Members are required to disclose. They are not required to divest, recuse, abstain, or look up from their brokerage accounts.
The Floor Votes
Warner's recent vote record runs mostly to procedural motions on Consumer Financial Protection Bureau-related resolutions and Iran war-powers questions. He voted Yea on three separate motions to proceed on CFPB rules in May, all of which were rejected. He voted Yea on two EPA emissions-related disapproval resolutions, also rejected. He's on the losing side of most of these chamber votes, which is what happens when you're in the minority.
The CFPB votes are market-relevant on their face: two of them concern overdraft practices and debt collection rules that directly affect the banking sector. Warner holds bank stocks. But these are floor votes, not committee markups. The Banking Committee conflict standard doesn't apply to floor votes where every senator casts a ballot. We're noting the sector proximity, not asserting something about it.
No vote-trade overlaps were flagged in the data for Warner's recent filings. The April 13 trading day preceded no specific floor vote we can match to the positions he opened.
The Number That Stays With You
Five wins. Eight losses. Minus 3.8 percent mean alpha across the scored sample. The senator from Virginia, former tech entrepreneur and venture capitalist, member of the Senate Banking Committee's Securities, Insurance, and Investment subcommittee, is trailing the index on the majority of trades we can score.
The best trade in the flagged committee-overlap set is the Fifth Third purchase, up 7.8 percent in 30 days. The worst is selling Amgen twice before the stock outperformed the market, leaving 12 to 14 points of alpha on the table across two transactions.
Warner is in the news this week for pushing legislation that benefits an industry his portfolio moved toward in April. He's also the Senate's most visible critic of the current intelligence leadership structure, a role that has nothing to do with any stock he owns. Both things are true at once. The filings don't distinguish between the two. They just show the trades.
The receipts are public. Make of them what you make of them.